The principal objective of the Clinical Core will be to recruit and maintain a panel of approximately 400 volunteer patients and controls at the ADRC, and 100 volunteer patients and controls as part of our Hispanic initiative at our satellite clinic in Chula Vista. The Core will recruit new subjects with a diagnosis of Mild Cognitive Impairment (MCI) and very early AD (MMSE greater than or equal to 20) to replace subjects who have become more impaired. A pool of 40 subjects will be maintained with DRS scores greater than or equal to 109 to meet the needs of our research protocols. During this competitive renewal cycle we will specifically increase our pool of MCI subject to 100 for Dr. Bondi's project on functional MRI. Particular emphasis will continue to be placed on the recruitment of normal controls over the age of 80, in order to meet the need for greater numbers of autopsied brains for clinical-pathotogical correlations and biochemical studies. Annual participant evaluations will include demographic, history, medical neurological, psychiatric, and neuropsychological examinations to aid in the diagnosis and to track yearly changes in cognitive and neurological progression. The evaluations provide a behavioral database that can be used by the various research projects associated with the ADRC and in addition provide longitudinal data on the course and progression of AD. The Clinical Core maintains banks of DNA, plasma, serum, and CSF, used by various UCSD investigators and collaborators at other institutions and in industry. The Clinical Core provides the resources for participation in a variety of multi-center clinical trials and collaborative studies using both subjects and data. Finally developmental work will be undertaken to improve our ability to diagnose early AD and to improve the diagnosis of other dementias such as dementia with Lewy bodies and fronto-temporal dementia.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG005131-25
Application #
7591071
Study Section
Special Emphasis Panel (ZAG1)
Project Start
Project End
Budget Start
2008-04-01
Budget End
2009-03-31
Support Year
25
Fiscal Year
2008
Total Cost
$1,366,288
Indirect Cost
Name
University of California San Diego
Department
Type
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Graves, Lisa V; Holden, Heather M; Van Etten, Emily J et al. (2018) New Yes/No Recognition Memory Analysis on the California Verbal Learning Test-3: Clinical Utility in Alzheimer's and Huntington's Disease. J Int Neuropsychol Soc 24:833-841
Kirson, Noam Y; Scott Andrews, J; Desai, Urvi et al. (2018) Patient Characteristics and Outcomes Associated with Receiving an Earlier Versus Later Diagnosis of Probable Alzheimer's Disease. J Alzheimers Dis 61:295-307
Barnes, Josephine; Bartlett, Jonathan W; Wolk, David A et al. (2018) Disease Course Varies According to Age and Symptom Length in Alzheimer's Disease. J Alzheimers Dis 64:631-642
Fong, Lauren K; Yang, Max M; Dos Santos Chaves, Rodrigo et al. (2018) Full-length amyloid precursor protein regulates lipoprotein metabolism and amyloid-? clearance in human astrocytes. J Biol Chem 293:11341-11357
Edmonds, Emily C; Ard, M Colin; Edland, Steven D et al. (2018) Unmasking the benefits of donepezil via psychometrically precise identification of mild cognitive impairment: A secondary analysis of the ADCS vitamin E and donepezil in MCI study. Alzheimers Dement (N Y) 4:11-18
Spencer, Brian; Brüschweiler, Sven; Sealey-Cardona, Marco et al. (2018) Selective targeting of 3 repeat Tau with brain penetrating single chain antibodies for the treatment of neurodegenerative disorders. Acta Neuropathol 136:69-87
Pottier, Cyril; Zhou, Xiaolai; Perkerson 3rd, Ralph B et al. (2018) Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurol 17:548-558
Burke, Shanna L; Maramaldi, Peter; Cadet, Tamara et al. (2018) Decreasing hazards of Alzheimer's disease with the use of antidepressants: mitigating the risk of depression and apolipoprotein E. Int J Geriatr Psychiatry 33:200-211
Weintraub, Sandra; Besser, Lilah; Dodge, Hiroko H et al. (2018) Version 3 of the Alzheimer Disease Centers' Neuropsychological Test Battery in the Uniform Data Set (UDS). Alzheimer Dis Assoc Disord 32:10-17
Qian, Winnie; Fischer, Corinne E; Schweizer, Tom A et al. (2018) Association Between Psychosis Phenotype and APOE Genotype on the Clinical Profiles of Alzheimer's Disease. Curr Alzheimer Res 15:187-194

Showing the most recent 10 out of 914 publications